Abstract
Background: Barrett’s esophagus (BE) is a premalignant lesion characterized by replacement of normal squamous epithelium with columnar epithelium. This lesion can progress to dysplasia and adenocarcinoma. Recently, the Fas receptor and retinoblastoma (Rb) protein have been described as important mediators of apoptosis and tumor suppression, respectively. This study was undertaken to examine their expression during the progression of metaplasia to adenocarcinoma in BE.
Methods: In a review of 56 adenocarcinomas arising in BE, the specimen blocks were examined using the immunohistochemical avidin-biotin-peroxidase complex technique. For each specimen, areas of normal epithelium were compared with areas of metaplasia, dysplasia, or carcinoma (when present). Monoclonal mouse anti-human antibodies were used to identify Rb protein (Rb-Ab5, 1/50 dilution; Oncogene Science) and the 40–50-kDa cell membrane Fas protein (APO-1/Fas, 1/5 dilution; DAKO Corp.).
Results: Loss of Rb staining was observed as the metaplasia progressed to dysplasia and carcinoma, indicating accumulation of unstainable aberrant protein. Conversely, Fas protein staining was undetectable or weak in normal or metaplastic epithelium, increasing in the areas of high-grade dysplasia and carcinoma. These differences were statistically significant (P < .001).
Conclusions: The accumulation of abnormal Rb protein during the progression of Barrett’s metaplasia to carcinoma leads to unsuppressed tumor growth. Fas overexpression may represent a cellular attempt to balance the uncontrolled tumor proliferation by promoting apoptosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
REFERENCES
Blot WJ, Devesa SS, Kneller RW, Fraumeni JFJr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287–1289.
Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510–513.
Spechler SJ, Goyal RK. Barrett’s esophagus. N Engl J Med 1986;315:362–371.
Van der Veen AH, Dees J, Blankensteijn JD, et al. Adenocarcinoma in Barrett’s oesophagus: an overated risk. Gut 1989;30:14–18.
Dent J, Bremner CG, Collen MJ, Haggitt RC, Spechler SJ. Barrett’s esophagus: Working Party report to the World Congress of Gastroenterology, Sydney, Australia, 1990. J Gastroenterol Hepatol 1991;6:1–22.
Mangla JC. Barrett’s epithelium: regression or no regression? N Engl J Med 1980;303:529–530.
Rustgi AK. Biomarkers for malignancy in the columnar-lined esophagus. Gastroenterol Clin North Am 1997;26:599–606.
Wang LD, Shi ST, Zhou Q, et al. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastria-cardia carcinogenesis. Int J Cancer 1994;59:514–519.
Hickey K, Grehan D, Reid IM, O’Briain S, Walsh TN, Hennessy TPJ. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994;74:1693–1698.
Casson AG, Kerkvliet N, O’Malley F. Prognostic value of p53 protein in esophageal adenocarcinoma. J Surg Oncol 1995;60:5–11.
Ireland AP, Clark GWB, DeMeester TR. The significance of p53 in clinical practice. Ann Surg 1997;225:17–30.
Soslow RA,Ying L, Altorki NK. Expression of acidic fibroblast growth factor in Barrett’s esophagus and associated esophageal adenocarcinoma. J Thorac Cardiovasc Surg 1997;114:838–343.
Swami S, Kumble S, Triadafilopoulos G. E-Cadherin expression in gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study. Am J Gastroenterol 1995;90:1808—1813.
Boynton RF, Huang Y, Blount PL, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 1991;51:5766–5769.
Ray GS, Lee JR, Nwokeji K, Mills LR, Goldenring JR. Increased immunoreactivity for Rab11, a small GTP-binding protein, in lowgrade dysplastic Barrett’s epithelia. Lab Invest 1997;77:503–511.
Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett’s esophagus. Oncogene 1996;13:1867–1873.
Al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and overexpression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993;54:213–219.
Kumble S, Omary MB, Cartwright CA, Triadafilopoulos G. Src activation in malignant and premalignant epithelia of Barrett’s esophagus. Gastroenterology 1997;112:348–356.
Daly JM, Karnell LH, Menck HR. National Cancer data base report on esophageal carcinoma. Cancer 1996;78:1820–1828.
Shimada Y, Imamura M, Shibagaki I, et al. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg 1997;226:162–168.
Katada N, Hinder RA, Smyrk TC, et al. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg 1997;132:728–733.
Hughes SJ, Nambu Y, Soldes OS, et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 1997;57:5571–5578.
Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456–1462.
Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449–1456.
Shi SR, Key ME, Kalza KL. Antigen retrieval in formalin-fixed paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741–748.
Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212–1219.
Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett’s esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119–129.
Nakamura T, Nekarda H, Hoelscher AH, et al. Prognostic value of DNA ploidy and c-ErbB-2 oncoprotein overexpression in adenocarcinoma of Barrett’s esophagus. Cancer 1994;73:1785–1794.
Knudson AG. Mutation and human cancer. Adv Cancer Res 1973;17:317–352.
Lee WH, Shew JY, Hong F, et al. The retinoblastoma susceptibility gene product is a nuclear phosphoprotein associated with DNA binding activity. Nature 1987;329:642–545.
Niculescu AB III, Chen X, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21 (Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998;18:629–543.
Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-Cdk complexes. Mol Cell Biol 1998;18:753–761.
Debatin KM, Goldman CK, Bamford R, Waldmann TA, Krammer PH. Monoclonal antibody mediated apoptosis in adult T cell leukemia. Lancet 1990;335:497–500.
Leithäuser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415–429.
Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132–1136.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Coppola, D., Schreiber, R.H., Mora, L. et al. Significance of Fas and Retinoblastoma Protein Expression During the Progression of Barrett’s Metaplasia to Adenocarcinoma. Ann Surg Oncol 6, 298–304 (1999). https://doi.org/10.1007/s10434-999-0298-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-999-0298-7